STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year

Sales under the U.S. 340B Drug Discount Program reached $100 billion in 2025, a 22.8% increase from the previous year. Expensive medicines accounted for 62% of spending, with Merck’s Keytruda and Gilead Sciences’ Biktarvy being the top two drugs by spending. The program requires drugmakers to offer 25-50% discounts to hospitals and clinics serving lower-income patients.